The relationship between the change in UGE and the glucose-lowering efficacy of SGLT-2 inhibitors in patients with type 2 diabetes mellitus has been researched; however, the conclusions drawn are inconsistent. This evidence concerns the gene SLC5A2 and diabetes mellitus.